Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Nichi-Iko Exits Turnaround Mode, Eyes Next Growth Phase
Nichi-Iko Pharmaceutical President and CEO Shingo Iwamoto declared the company’s turnaround complete on July 7, saying three consecutive years of core operating profit growth and significant improvements in manufacturing and quality assurance have brought its restructuring phase to an end.…
To read the full story
Related Article
- And Pharma Group Subsidiaries Team Up for First Joint Promotion
October 23, 2025
- Nichi-Iko Shows Signs of Recovery but Restructuring Still Underway: CEO
September 5, 2025
- Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President
January 29, 2025
- Shingo Iwamoto Sworn in as New Chief of Nichi-Iko; Tamura Bows Out
March 9, 2023
- Creditors Approve Nichi-Iko’s Turnaround Scheme, Grants Debt Waiver of 98.5 Billion Yen
January 5, 2023
BUSINESS
- Moderna’s mNEXSPIKE Grabs Japan Approval for XFG Variant
August 20, 2026
- Nipro’s Forxiga AG to Hit Shelves on September 4
August 20, 2026
- Teijin Taps CAR-T Expert Campana as Technical Advisor
August 20, 2026
- Sandoz Gets Broader Label for Genotropin Biosimilar
August 20, 2026
- Mochida to Take Over Topiloric from Fuji Yakuhin in October
August 20, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…